Financial News
Gilead's twice-yearly shot cut HIV infections by 96% in trial
September 12, 2024 at 09:29 AM EDT
The data sets the stage for likely approval of Gilead's Lenacapavir for HIV prevention.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
